Embrella CE marks blood clot deflector
This article was originally published in Clinica
Executive Summary
Embrella Cardiovascular has CE marked its Embrella Embolic Deflector for sale in Europe. The device acts as a protective shield, deflecting blood clots from arteries that lead to the head and stopping them from blocking blood vessels in the brain. This should decrease the incidence of ischaemic stroke during procedures such as transcatheter aortic valve implantation (TAVI), which can dislodge debris and calcific particles that are found in diseased arteries. TAVI is approved in Europe for patients with severe aortic stenosis, and Embrella (Wayne, Pennsylvania) expects the global market to grow from $200m in 2009 to over $1.7bn in 2015. The company hopes its device will become the standard of care in all TAVI procedures.